New combo attack on sarcoma: radiation, chemo, and immunotherapy before surgery
NCT ID NCT05774275
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This trial is testing whether giving a combination of radiation, chemotherapy, and an immunotherapy drug before surgery can help people with high-risk soft tissue sarcoma. The study will include 52 adults whose tumors are large or hard to remove. The goal is to see if this approach shrinks tumors enough to improve surgery results and lower the chance of the cancer coming back.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Pegylated liposomal doxorubicin, doxorubicin hydrochloride, sintilimab (anti-PD-1), and radiotherapy
- What this could lead to
- If successful, this combination could shrink high-risk sarcomas before surgery, potentially improving surgical outcomes and reducing recurrence.
- What could go wrong
- This is an early-phase trial with only 52 participants, so results may not apply broadly. The combination of treatments may cause significant side effects.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HIGH-RISK LOCALIZED SOFT TISSUE SARCOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Fudan University Shanghai Cancer Center
RECRUITINGShanghai, Shanghai Municipality, 200032, China